Kane Biotech to Participate in Maxim Group LLC Inaugural Emerging Growth Conference
Kane Biotech Inc. (OTCQB: KNBIF) announced that CEO Marc Edwards will present at the Emerging Growth Virtual Conference on March 17-18, 2021. The event will feature discussions and presentations from various leaders in the Biotech and Healthcare sectors. Edwards expressed excitement about sharing the company's growth story, highlighting successes in commercializing products across three markets and securing government funding. Kane Biotech specializes in technologies that prevent and remove microbial biofilms, holding a robust portfolio of intellectual property.
- None.
- None.
WINNIPEG, Manitoba, March 11, 2021 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (the “Company” or “Kane”), announced today that Marc Edwards, CEO will be presenting at the Inaugural Emerging Growth Virtual Conference presented by Maxim Group LLC.
The conference will take place on March 17 and 18 from 9:00am – 5:00pm EDT featuring roundtable discussions with C-Suite executives moderated by Maxim Research analysts, fireside chats with live Q&A and presentations. During this virtual conference, Kane Biotech will present along with other important voices in the Biotech and Healthcare sectors.
“I’m delighted to have the opportunity to present our story to the investment community. We’re rapidly commercializing in three markets thanks to the strategic partnerships we’re putting in place and the multiple sources of government funding we’ve secured,” commented Marc Edwards, CEO Kane Biotech.
About Maxim Group LLC.
Maxim Group LLC is a full-service investment banking, securities and wealth management firm headquartered in New York. The Firm provides a full array of financial services including investment banking; private wealth management; and global institutional equity, fixed-income and derivatives sales & trading, equity research and prime brokerage services. Maxim Group is a registered broker-dealer with the U.S. Securities and Exchange Commission (SEC) and the Municipal Securities Rulemaking Board (MSRB). Member of FINRA SIPC, and NASDAQ. To learn more about Maxim Group, visit maximgrp.com
About Kane Biotech Inc.
Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (52 patents and patents pending, trade secrets and trademarks) and products developed by the Company's own biofilm research expertise and acquired from leading research institutions. StrixNB™, DispersinB®, Aledex™, bluestem™, bluestem®, silkstem™, goldstem™, coactiv+™, coactive+®, DermaKB™ and DermaKB Biofilm™ are trademarks of Kane Biotech Inc. The Company is listed on the TSX Venture Exchange under the symbol "KNE" and on the OTCQB Venture Market under the symbol “KNBIF”.
For more information, please visit www.kanebiotech.com, or contact
| Marc Edwards | Ray Dupuis | Graham Farrell |
| Chief Executive Officer | Chief Financial Officer | Investor Relations |
| Kane Biotech Inc | Kane Biotech Inc | Harbor Access LLC |
| medwards@kanebiotech.com | rdupuis@kanebiotech.com | Graham.Farrell@HarborAccessllc.com |
| +1 (514) 910-6991 | +1 (204) 298-2200 | +1 (416) 842 9003 |
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Information
This press release contains certain statements regarding Kane Biotech Inc. that constitute forward-looking information under applicable securities law. These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. These risks and uncertainties include, but are not limited to, risks relating to the Company’s: (a) financial condition, including lack of significant revenues to date and reliance on equity and other financing; (b) business, including its early stage of development, government regulation, market acceptance for its products, rapid technological change and dependence on key personnel; (c) intellectual property including the ability of the Company to protect its intellectual property and dependence on its strategic partners; and (d) capital structure, including its lack of dividends on its common shares, volatility of the market price of its common shares and public company costs. Further information about these and other risks and uncertainties can be found in the disclosure documents filed by the Company with applicable securities regulatory authorities, available at www.sedar.com. The Company cautions that the foregoing list of factors that may affect future results is not exhaustive.
COVID-19 Pandemic
Since December 31, 2019, the COVID-19 outbreak of the novel strain of coronavirus, SARS- CoV-2, has resulted in a widespread health crisis that has affected economies and financial markets around the world resulting in an economic downturn. The effects of this pandemic on the Company may include decreased customer demand, interruptions to supply chains, manufacturing activities and research and development programs and increased government regulations or interventions. The duration and impact of the COVID-19 outbreak is unknown at this time and it is not possible to reliably estimate the length and severity of these developments nor the impact of these developments on the financial results and condition of the Company in future periods.
Source: Kane Biotech Inc
FAQ
When is the Emerging Growth Virtual Conference for Kane Biotech?
Who will represent Kane Biotech at the virtual conference?
What is the focus of Kane Biotech's presentation at the conference?
What does Kane Biotech specialize in?
What stock symbol is associated with Kane Biotech?
